CN1443551A - Chinese medicine preparation for curing hyperosteogeny and its preparation method - Google Patents
Chinese medicine preparation for curing hyperosteogeny and its preparation method Download PDFInfo
- Publication number
- CN1443551A CN1443551A CN 02111036 CN02111036A CN1443551A CN 1443551 A CN1443551 A CN 1443551A CN 02111036 CN02111036 CN 02111036 CN 02111036 A CN02111036 A CN 02111036A CN 1443551 A CN1443551 A CN 1443551A
- Authority
- CN
- China
- Prior art keywords
- radix
- preparation
- chinese medicine
- root
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a Chinese medicine preparation for curing hyperosteogeny. Said Chinese medicine preparation is made up by using 17 Chinese medicinal materials of white peony root, eucommia bark, dipsacus root and others. Said invented preparation has the functions of boosting liver and kidney, supplementing qi and blood, removing wind and dampness, relieving inflammation and stopping pain, etc.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field.Be specifically related to a kind of Chinese medicine preparation and preparation method for the treatment of hyperosteogeny.
Background technology
Hyperosteogeny is a kind of common multiple disease, is osteoarticular a kind of degeneration.With advancing age, its sickness rate also increases thereupon, and the old people more than 60 years old nearly all has hyperosteogeny in various degree, especially cervical vertebra, lumbar vertebra sickness rate height, usually bring a series of chronic diseases, as: head, neck, shoulder, waist, carry on the back, have a pain in the leg pain, numbness etc.
Because the hyperosteogeny course of disease is long, touching refractory, repeatability is big, and clinical further consultation rate height is difficult for treatment.Main both at home and abroad treatment hyperosteogeny is divided operation treatment and non-operative treatment (traction, massage, physical therapy, medicine), there is no effective method for treatment and specific medicament on the market.
Summary of the invention
Technical problem to be solved of the present invention is to solve the problems of the technologies described above, and develops the Chinese medicine preparation of a kind of drug effect height, taking convenience, no obvious toxic-side effects.
,：10-40 1-8 1-8 1-81-8 1-8 1-8 1-81-8 2-10 ( ) 1-41-4 2-10 ( ) 1-8 ( ) 1-4 ( ) 1-4 ( ) 1-8：10-30 2-6 2-6 2-62-6 2-6 2-6 2-62-6 3-9 ( ) 1-31-3 3-9 ( ) 2-6 ( ) 1-3 ( ) 1-3 ( ) 2-6
Wherein best proportioning is: 4 parts of 4 parts of Olibanums of the Radix Paeoniae Alba 21.6 parts of Cortexs Eucommiae, 4 parts of Radix Dipsacis, 4 parts of Radix Achyranthis Bidentataes, 4 parts of Radix Salviae Miltiorrhizaes, 4 portions of Caulis Spatholobis, 4 parts of Flos Carthamis, 4 portions of Radix Glycyrrhizaes, 4 parts of Radix Saposhnikoviaes, 6 parts of Rhizoma Atractylodis Macrocephalaes of 4 parts of Radix Clematidis (system) 2 parts of Poria, 6 parts of Rhizoma Arisaematiss of 2.4 portions of Fructus Chaenomeliss (system) (system), 2 parts of Rhizoma Drynariae of 2 parts of Myrrha (processed) (stir-fry)
Radix Paeoniae Alba suppressing the hyperactive liver pain relieving during the present invention forms is nourished blood, treating the liver gas discord, and muscle arteries and veins spasm and pain is a monarch drug, Radix Saposhnikoviae expelling wind and cold, removing dampness to relieve pain; Rhizoma Arisaematis looses that wind-dryness is wet, expectorant, Radix Clematidis, Fructus Chaenomelis damp eliminating Shujin, and four flavors share at the wet exopathogen invasion and attack of wind and cold, symptomatic treatment, and with the passing of time arthromyodynia is condensed into expectorant, the puckery one-tenth stasis of blood of blood, thereby with Radix Salviae Miltiorrhizae, Flos Carthami blood circulation promoting and blood stasis dispelling, Caulis Spatholobi channels sootheing and network vessel quickening; Olibanum, Myrrha blood circulation promoting and blood stasis dispelling again can pain relievings, and the pain relieving of principal drug assistance migratory arthralgia is ministerial drug altogether, and arthromyodynia is weakened body resistance to be this, so dry with the Rhizoma Atractylodis Macrocephalae, Poria replenishing QI to invigorate the spleen, the Cortex Eucommiae, Radix Dipsaci, Radix Achyranthis Bidentatae, Rhizoma Drynariae, invigorating the liver and kidney, waist knee joint by force are adjuvant drug.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is a messenger drug.The side of closing plays nourishing liver and kidney altogether, expelling wind and removing dampness, and blood circulation promoting and blood stasis dispelling, the merit of strong muscle collateral dredging has good efficacy to hyperosteogeny.
The present invention has following effect through pharmacodynamic experiment:
Extractum 2.5～2.0/kg dosage of the present invention is irritated stomach to animal, and swollen and carrageenan-induced rat toes swelling all has the obvious suppression effect to rat granuloma, and all there is obvious inhibitory action in mice glue chamber and rat skin capillary permeability; Mice acetic acid and formaldehyde caused the button that pain causes and lick the foot reaction the obvious suppression effect.
To sum up the result can think that this product reduces aspects such as capillary permeability and analgesia certain effect is all arranged at antiinflammatory, has curative effect by many-sided effectiveness combination.
The present invention proves through toxicological experiment, has no side effect.
Acute toxicity test: acute toxicity test of the present invention, once give mouse stomach extractum 16.5g/kg of the present invention, be equivalent to crude drug amount 68g/kg, observed continuously 7 days, do not see any toxic reaction and death.Mtd test shows, gives mouse stomach each at interval 4 hour three times with above-mentioned dosage in 24 hours, and total dosage is 204g crude drug/kg, is equivalent to 209 times (people's dosage every day is 15.0g extractum, and amounting to the crude drug amount is 61.5g) of clinical population dosing.Illustrate that this product toxicity is very little, clinical plan consumption is safer.
Long term toxicity test: Canis familiaris L. is used in this test, gives the present invention three months continuously, observes its toxic reaction and its order of severity to body.Observed result shows, heavy dose of made serum T-BIL raises, the visible liver cell proliferation phenomenon of pathological examination, showing has a tame toxic action, but drug withdrawal is after 15 days, above-mentioned phenomenon all disappears, the present invention is more little to the influence of liver in prompting, and is reversible, and other observed index is normal substantially, with compare no significant difference, thereby test confirms that this medicine uses safer down in clinical dosage.
The present invention is through Hubei Prov. Inst. of Traditional Chinese Medicine, Liaoning Prov. Traditional Chinese Medicine Inst, attached institute of Traditional Chinese Medicinal College of Liaoning, Shenyang Inst. of Traditional Chinese Medicine's clinical trial prove, this product has liver and kidney tonifying, fills blood, wind-damp dispelling, remove the arthralgia pain effect, simultaneously, has anti-inflammatory and analgesic effect again.400 routine lumbar vertebra osteoarthritis have been carried out the clinical observation of system, and the result is as follows:
1. the present invention is 34.33% to the obvious effective rate of spondylitis of lumbar hyperplasia, and total effective rate is 83.67%.
2. the present invention the improvement of pain symptom occurs to spondylitis of lumbar hyperplasia, and rising at the 5th day just has significant analgesia role.With matched group highly significant difference is arranged relatively after the 10th day, illustrate that the present invention can better improve the pain of spondylitis of lumbar hyperplasia, and be better than resisting hyperosteogeny sheet matched group.
3. the present invention had clear and definite effect to the improvement of the tenderness of spondylitis of lumbar hyperplasia appearance after the 10th day, and is better than matched group after the 20th day.Illustrate that the present invention can alleviate the tenderness of spondylitis of lumbar hyperplasia, but effect is slower.
4. the present invention is better than matched group to the movable function that spondylitis of lumbar hyperplasia occurs, but onset time is slower, and curative effect prolongs in time and improves.
The present invention clinical just with during, gastrointestinal symptom and headache, symptom of diarrhea appear in indivedual cases, but continue to disappear after the medication, totally have no side effect.As seen the present invention is the active drug that treatment waist hyperplastic spondylitis improves its symptom.
Another technical issues that need to address of the present invention have provided a kind of preparation method for the treatment of the Chinese medicine preparation of hyperosteogeny, this method is by recipe quantity the Radix Paeoniae Alba, the Cortex Eucommiae, Radix Dipsaci, Radix Achyranthis Bidentatae, Radix Salviae Miltiorrhizae, Caulis Spatholobi, Flos Carthami, Radix Glycyrrhizae, Radix Saposhnikoviae, Radix Clematidis, the Rhizoma Atractylodis Macrocephalae (system), Poria, Fructus Chaenomelis, Rhizoma Arisaematis (system), Myrrha (processed) and Rhizoma Drynariae (stir-fry) to be decocted with water secondary, filter, merge secondary filtrate, concentrate, press preparation then and need use the conventional method drying, add adjuvant and make solid preparation or concentrated solution is added adjuvant and be mixed with liquid preparation.
Preparation of the present invention adopts Chinese medicine composition to form drug effect height, taking convenience, no obvious toxic-side effects.
The specific embodiment
Embodiment 1
1. by weight ratio: Radix Paeoniae Alba 108kg Cortex Eucommiae 20kg Radix Dipsaci 20kg Radix Achyranthis Bidentatae 20kg Rhizoma Arisaematis (system) the 20kg Rhizoma Atractylodis Macrocephalae (system) 10kg Poria 12kg Fructus Chaenomelis 30kg Olibanum (system) 10kg Myrrha (processed) 10kg Radix Salviae Miltiorrhizae 20kg Caulis Spatholobi 20kg Flos Carthami 20kg Rhizoma Drynariae (stir-fry) 20kg Radix Glycyrrhizae 20kg
More than 17 the flavor, decoct with water secondary, each 8 times of amounts, each decocted 1.5 hours, filtered, and the merging filtrate concentrating under reduced pressure becomes the concentrated solution of relative density 1.08-1.11 (60 ℃), spray drying adds an amount of aspartame, dextrin, mixing in the xeraphium, ethanol liquid with polyvinylpyrrolidone (PVP), granulate drying under reduced pressure, granulate, packing, promptly.Embodiment 2 Radix Paeoniae Alba 270g Cortex Eucommiae 40g Radix Dipsaci 60g Radix Achyranthis Bidentatae 50g Radix Clematidis 75g Radix Saposhnikoviae 50g Rhizoma Arisaematis (system) the 50g Rhizoma Atractylodis Macrocephalae (system) 25g Poria 30g Fructus Chaenomelis 75g Olibanum (system) 25g Myrrha (processed) 25g Radix Salviae Miltiorrhizae 50g Caulis Spatholobi 40g Flos Carthami 50g Rhizoma Drynariae (stir-fry) 50g Radix Glycyrrhizae 50g
More than 17 flavors, decoct with water secondary, each 8 times of amounts, each decocted 1.5 hours, filtered, filtrate merges, and is evaporated to relative density, the extractum of 1.35-1.38 (80 ℃) is got 1 part of extractum, 2 parts of sucrose, 1.5 parts in dextrin.Make granule with ethanol, make 1000g, drying, packing, that is, and every bag of 20g.
Claims (3)
1. Chinese medicine preparation for the treatment of osteoproliferation is characterized in that this Chinese medicine preparation is comprised of with the weight proportion of arbitrary proportion following ingredients that active component and pharmaceutical carrier form: root of herbaceous peony 10-40 part bark of eucommia 1-8 part teasel root 1-8 part root of bidentate achyranthes 1-8 part red sage root 1-8 part reticulate millettia 1-8 part safflower 1-8 part Radix Glycyrrhizae 1-8 part windproof 1-8 part root of Chinese clematis 2-10 part bighead atractylodes rhizome (system) 1-4 part Poria cocos 1-4 part pawpaw 2-10 part rhizoma arisaematis (system) 1-8 part frankincense (system) 1-4 part myrrh (system) 1-4 rhizome of davallia (stir-fry) 1-8 part
2. the Chinese medicine preparation of a treatment hyperosteogeny as claimed in claim 1 is characterized in that its active component weight proportion consists of: Radix Paeoniae Alba 10-30 part Cortex Eucommiae 2-6 part Radix Dipsaci 2-6 part Radix Achyranthis Bidentatae 2-6 part Radix Salviae Miltiorrhizae 2-6 part Caulis Spatholobi 2-6 part Flos Carthami 2-6 part Radix Glycyrrhizae 2-6 part Radix Saposhnikoviae 2-6 part Radix Clematidis 3-9 part Rhizoma Atractylodis Macrocephalae (system) 1-3 part Poria 1-3 part Fructus Chaenomelis 3-9 part Rhizoma Arisaematis (system) 2-6 part Olibanum (system) 1-3 part Myrrha (processed) 1-3 Rhizoma Drynariae (stir-fry) 2-6 part
3. the preparation method of the Chinese medicine preparation of a treatment hyperosteogeny as claimed in claim 1, it is characterized in that this method is by recipe quantity the Radix Paeoniae Alba, the Cortex Eucommiae, Radix Dipsaci, Radix Achyranthis Bidentatae, Radix Salviae Miltiorrhizae, Caulis Spatholobi, Flos Carthami, Radix Glycyrrhizae, Radix Saposhnikoviae, Radix Clematidis, the Rhizoma Atractylodis Macrocephalae (system), Poria, Fructus Chaenomelis, Rhizoma Arisaematis (system), Myrrha (processed) and Rhizoma Drynariae (stir-fry) to be decocted with water, filter, concentrate, press preparation then and need use the conventional method drying, add adjuvant and make solid preparation or concentrated solution is added adjuvant and be mixed with liquid preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02111036 CN1255150C (en) | 2002-03-13 | 2002-03-13 | Chinese medicine preparation for curing hyperosteogeny and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02111036 CN1255150C (en) | 2002-03-13 | 2002-03-13 | Chinese medicine preparation for curing hyperosteogeny and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1443551A true CN1443551A (en) | 2003-09-24 |
| CN1255150C CN1255150C (en) | 2006-05-10 |
Family
ID=27811195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02111036 Expired - Lifetime CN1255150C (en) | 2002-03-13 | 2002-03-13 | Chinese medicine preparation for curing hyperosteogeny and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1255150C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300176C (en) * | 2005-06-29 | 2007-02-14 | 中国药科大学 | New saponin and its derivative, its preparation method and its use in medicine |
| CN100411645C (en) * | 2005-10-26 | 2008-08-20 | 蒋保珍 | Hyperosteogeny treating medicine |
| CN101390967B (en) * | 2008-11-05 | 2010-12-08 | 杨顺庆 | Medicine composition for treating osteoporosis |
| CN104383366A (en) * | 2014-12-05 | 2015-03-04 | 广州共禾医药科技有限公司 | Traditional Chinese medicine composition for treating osteoproliferation |
| CN112546145A (en) * | 2020-11-19 | 2021-03-26 | 湖南兰嗅生物科技有限公司 | Spur removing paste and preparation method thereof |
| CN113134074A (en) * | 2021-06-02 | 2021-07-20 | 韩文珍 | A Chinese medicinal composition for treating hyperosteogeny, and its preparation method |
-
2002
- 2002-03-13 CN CN 02111036 patent/CN1255150C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300176C (en) * | 2005-06-29 | 2007-02-14 | 中国药科大学 | New saponin and its derivative, its preparation method and its use in medicine |
| CN100411645C (en) * | 2005-10-26 | 2008-08-20 | 蒋保珍 | Hyperosteogeny treating medicine |
| CN101390967B (en) * | 2008-11-05 | 2010-12-08 | 杨顺庆 | Medicine composition for treating osteoporosis |
| CN104383366A (en) * | 2014-12-05 | 2015-03-04 | 广州共禾医药科技有限公司 | Traditional Chinese medicine composition for treating osteoproliferation |
| CN104383366B (en) * | 2014-12-05 | 2017-07-28 | 广州共禾医药科技有限公司 | A kind of Chinese medicine composition for treating osteoproliferation |
| CN112546145A (en) * | 2020-11-19 | 2021-03-26 | 湖南兰嗅生物科技有限公司 | Spur removing paste and preparation method thereof |
| CN113134074A (en) * | 2021-06-02 | 2021-07-20 | 韩文珍 | A Chinese medicinal composition for treating hyperosteogeny, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255150C (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178895A (en) | Chinese medicine composition for treating orthopedic disorders and preparation method thereof | |
| CN101703732B (en) | Chinese medicinal ointment for treating herpes zoster and preparation method thereof | |
| CN102370949A (en) | Chinese medicinal compound preparation for treating cholecystitis and preparation method thereof | |
| CN1899598A (en) | Combined medicine for preventing and treating rheumatism, rheumatoid, protrusion of intervertebral disc and hyperosteogeny | |
| CN1255150C (en) | Chinese medicine preparation for curing hyperosteogeny and its preparation method | |
| CN1256931A (en) | Traditional Chinese medicine for treating uremia and fortifying kidney and productive method thereof | |
| CN100387291C (en) | Medicine for treating pulmonary tuberculosis | |
| CN1053189A (en) | The preparation method of " promoting blood circulation and restoring paralysis pills " | |
| CN100531789C (en) | Chinese medicine for treating injury | |
| CN1351872A (en) | Chinese herbal medicine for curing comedo and acne | |
| CN102028831B (en) | Traditional Chinese medicine composition for treating tumors or cancers and preparation method thereof | |
| CN104288328A (en) | Traditional Chinese medicinal composition for treating herpes zoster and preparation method thereof | |
| CN100402065C (en) | Capsule for treating gout and preparation process thereof | |
| CN1175839C (en) | Chinese medicine liquid for treating rheumatism and preparation method thereof | |
| CN105832941A (en) | External-use ointment for treating tenosynovitis and preparation method thereof | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN101579507B (en) | Medicine for treating gall stones and preparation method thereof | |
| CN105125658A (en) | Granules with effects of eliminating obstruction to activate collaterals and preparation method thereof | |
| CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter | |
| CN1322558A (en) | Liver cancer resisting medicine | |
| CN103028058B (en) | Traditional Chinese medicine composition for treating feebleness | |
| CN103330792B (en) | Traditional Chinese medicine lotion for treating tinea pedes | |
| CN111388604B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN1057465C (en) | Medicine for treating chronic kidney disease and its prepn. method | |
| CN1062159C (en) | Medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060510 |
|
| CX01 | Expiry of patent term |